SHARE

Report Highlights

Latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors – Pipeline Review, H1 2018, provides an overview of the Neuroendocrine Tumors pipeline landscape. Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 2, 1, 30, 24, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Neuroendocrine Tumors pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Neuroendocrine Tumors are: 2X Oncology Inc, AbbVie Inc, Advanced Accelerator Applications SA, Aegis Therapeutics LLC, Amgen Inc, Aquestive Therapeutics, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Celgene Corp, Cielo Therapeutics Inc, Cleave Biosciences Inc, Crinetics Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Dauntless Pharmaceuticals Inc, DexTech Medical AB, Eli Lilly and Co, Esperance Pharmaceuticals Inc, Exelixis Inc, Foresee Pharmaceuticals Co Ltd, Fujifilm Holdings Corporation, Hutchison MediPharma Ltd, Ignyta Inc, Ipsen SA, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Madrigal Pharmaceuticals Inc., Mateon Therapeutics Inc, Merck & Co Inc, Merck KGaA, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, Molecular Templates Inc, MolMed SpA, Novartis AG, Peptron Inc, Pfizer Inc, Pharma Mar SA, Progenics Pharmaceuticals Inc, Provectus Biopharmaceuticals Inc, Regulaxis SAS, Strongbridge Biopharma plc, Taiwan Liposome Company Ltd, Tarveda Therapeutics Inc, Valeant Pharmaceuticals International Inc, Vascular Biogenics Ltd, Xencor Inc.

Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/062923947/neuroendocrine-tumors-pipeline-review-h1-2017/inquiry?source=apexnews&Mode=01

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors.
    2. The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Neuroendocrine Tumors therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Neuroendocrine Tumors therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Browse full Report at: https://www.marketinsightsreports.com/reports/062923947/neuroendocrine-tumors-pipeline-review-h1-2017?source=apexnews&Mode=01

Report Coverage:

The objective of updating report coverage is to ensure that it represents the most up to date vision of the industry possible. The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic Products that are in the course of development, however, if a drug is solely used for research purpose, where the Intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Our aims to cover major news events and deals in the pharmaceutical Industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from our Expert Panel.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.

List of Tables Mentioned are:

1) Number of Products under Development for Neuroendocrine Tumors, H1 2018, 2) Number of Products under Development by Companies, H1 2018, 3) Number of Products under Development by Universities/Institutes, H1 2018, 4) Products under Development by Companies, H1 2018, 5) Products under Development by Universities/Institutes, H1 2018, 6) Number of Products by Stage and Target, H1 2018, 7) Number of Products by Stage and Mechanism of Action, H1 2018, 8) Number of Products by Stage and Route of Administration, H1 2018, 9) Number of Products by Stage and Molecule Type, H1 2018